

Cover Story
By Matthew Bin Han Ong
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
By Jordan Williams
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- ACOG says it will no longer accept federal funding
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- The Med Student’s Memo – Research Concerns
- In The Headlines: Late poet Andrea Werblin Reid’s husband talks about publishing her final collection about dying from ovarian cancer